Dutch biotech UniQure NV said its experimental gene therapy for a blood disorder benefited some patients in an early-stage study, offering a rare ray of hope in gene therapy research plagued by a series of failed trials. Janney Capital Markets analyst Debjit Chattopadhyay said UniQure’s data looked better than that of Baxalta Inc’s rival drug. Gene therapy research, which aims to insert corrective genes into malfunctioning cells, has been dogged by a series of disappointments and safety concerns.
Go here to read the rest:
UniQure shares jump on promising gene therapy data